Empirical vs Tailored Therapy for H. Pylori Infection

Unknown 62 enrolled Seoul National University Hospital

RandomizedParallel-groupOpen-labelTreatment

Summary

We aimed to compare the efficacy of genotypic resistance-guided tailored therapy vs empirical therapy for eradication of Helicobacter pylori (H. pylori) infection in randomized controlled trials.

Timeline

Start: 2019-01-04
Primary completion: 2019-08-31
Completion: 2019-08-31

Outcome

Missed primary endpoint

paper H. pylori was eradicated in 27 patients (75.0%), given empirical therapy and 32 patients (88.9%) treated with tailored therapy (P = 0.136) in intention-to-treat analysis. PMID 33094958 ↗

Publications

Kim JL, Cho SJ, Chung SJ, Lee A, Choi J, Chung H, Kim SG. Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial. Clin Transl Gastroenterol. 2020 Sep;11(9):e00194. doi: 10.14309/ctg.0000000000000194.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Amoxicillin	Other / unclassified	1 g	—
Subject	Bismuth Potassium Citrate	Unknown	300 mg	—
Subject	Clarithromycin	Small molecule	500 mg	—
Subject	Metronidazole	Small molecule	500 mg	—
Subject	Tetracycline	Unknown	500 mg	—
Background	Esomeprazole	Small molecule	40 mg	—